Global Diverticular Treatment Market Overview:
Diverticular disease is a digestive disorder that causes sacs or small bulges to develop in the large intestine wall. These sacs can develop in any part of the colon, but they are most common in the sigmoid colon. Diverticular disease is caused by a variety of factors including a low-fiber diet, lack of physical activity, and some medications such as anti-inflammatory drugs, vitamin D deficiency, obesity, and smoking. The growing prevalence and recurrence of diverticular disease is expected to be the major factor driving the growth of the diverticular disease therapeutics market over the forecast period.
- Growing Prevalence and Recurrence of Diverticular Disease
- Rise in Cigarette Smoking Population
- Increase in Investment in R&D
- Stringent Regulatory Factors
- Increasing Advancement in The Treatment Techniques
- Launch and addition of new therapies
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Shire Plc. (United States), Cook Group Incorporated (United States), Allergan plc (Ireland), Salix Pharmaceuticals Inc. (United States), novoGI, Inc. (United States), Novartis AG (Switzerland), Glaxosmithkline Inc. (United Kingdom), Pfizer Inc. (United States), Gilead Sciences, Inc. (United States) and Fresenius Kabi AG (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Diverticular Treatment market by 2026. Considering Market by Indication, the sub-segment i.e. Symptomatic Uncomplicated Diverticular Disease will boost the Diverticular Treatment market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Diverticular Treatment market. Considering Market by Diagnosis, the sub-segment i.e. CT Scan will boost the Diverticular Treatment market.
Cook Group Incorporated is evaluating Hemospray device in phase 2 clinical trial to control colonic bleeding in severe diverticular disease., and Shire Plc. is evaluating SPD476 and SPD476 MMX in phase 3 clinical trial to reduce recurrence of diverticulitis.
What Can be Explored with the Diverticular Treatment Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Diverticular Treatment Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Diverticular Treatment
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Diverticular Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Diverticular Treatment market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Diverticular Treatment Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.